维奈克拉联合阿扎胞苷对比D-CAG方案治疗老年复发难治性急性髓系白血病
前瞻性随机研究纳入50例老年复发难治性急性髓系白血病患者,比较VA与D-CAG挽救治疗的疗效与安全性。两组客观缓解率和复合完全缓解率无显著差异,VA组持续缓解时间显著更优,但皮疹和腹泻发生率更高,晚期复发患者疗效优于早期复发及难治组。
要点
- VA与D-CAG方案在老年RR-AML中疗效相当,ORR和cCR率无显著差异。
- VA组持续缓解时间显著优于D-CAG组(未达到对6个月,P=0.023)。
- 晚期复发患者对两种方案疗效优于早期复发及难治组,移植患者预后更优。
核心结论
- VA及D-CAG方案用于老年RR-AML的疗效相当。
- 晚期复发AML患者对两种挽救化疗的疗效优于早期复发及难治组。
- VA组持续缓解时间较D-CAG组存在显著优势。
研究设计与样本
- 前瞻性随机研究,采用随机信封,计划入组50例。
- 纳入2021年1月至2024年6月老年RR-AML患者,接受至少1个疗程VA或D-CAG治疗并完成评估。
- VA组22例,中位年龄63.0(60.8~69.3)岁;D-CAG组28例,中位年龄66.5(62.3~69.0)岁。
- 主要终点为ORR和cCR率,次要终点为OS、DOR和安全性。
主要发现
- VA组和D-CAG组1个疗程ORR分别为68.2%(15/22)和53.6%(15/28),差异无统计学意义(P>0.05)。
- VA组和D-CAG组1个疗程cCR率分别为68.2%(15/22)和46.4%(13/28),差异无统计学意义(P>0.05)。
- 伴AML-MR基因突变患者中VA组cCR率为85.7%(6/7),D-CAG组为40.0%(4/10)。
- 中位随访19(11~48.5)个月,整体中位OS为16个月,VA组19个月,D-CAG组11个月(P=0.189)。
- 30例达cCR患者中VA组DOR未达到,D-CAG组为6个月(P=0.023)。
关键数值与推荐
- VA组皮疹发生率27.3%对3.6%(P=0.047),腹泻发生率40.9%对7.1%(P=0.012),均高于D-CAG组。
- 早期复发患者采用两种再诱导方案的cCR率均不到40%。
- 晚期复发患者VA组5例中4例获cCR,D-CAG组2例均获cCR。
临床怎么用
- 老年RR-AML可选用VA或D-CAG方案进行挽救治疗,两者疗效相当。
- 晚期复发患者对两种方案疗效更优,可优先考虑挽救化疗。
- VA方案需关注皮疹和腹泻不良反应。
- 挽救治疗后达cCR并接受异基因造血干细胞移植者预后更优。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the efficacy and safety of venetoclax (VEN) combined with azacitidine (AZA) (VA) versus decitabine combined with cytarabine+aclarubicin+granulocyte colony-stimulating factor (CAG) (D-CAG) regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia (RR-AML) . Methods: This prospective randomized study was conducted using VA and D-CAG regimens for the salvage treatment of elderly patients with RR-AML. A sealed envelope was used for randomization, with a planned enrollment of 50 patients. The primary endpoints were objective response rate (ORR) and composite complete remission (cCR) rate, whereas the secondary endpoints included overall survival (OS), duration of remission (DOR), and safety. Results: From January 2021 to June 2024, 50 elderly patients with RR-AML received at least one cycle of either VA or D-CAG treatment and completed efficacy and safety assessments. The VA group comprised 22 patients with a median age of 63.0 (range: 60.8-69.3) years, and the D-CAG group included 28 patients with a median age of 66.5 (range: 62.3-69.0) years. DNA methylation gene mutations were the most frequent, comprising 8 cases (36.4%) in the VA group and 9 cases (32.1%) in the D-CAG group. The ORR was 68.2% (15/22) and 53.6% (15/28) and the cCR rate was 68.2% (15/22) and 46.4% (13/28) in the VA and D-CAG groups, respectively. No significant difference in ORR or cCR was observed between the two groups. Subgroup analysis revealed that the cCR rate in the VA group with AML-MR gene mutations was 6/7, which was higher than 4/10 in the D-CAG group. Patients were categorized into early relapse, late relapse, and refractory groups. The cCR rate for early relapse was below 40% with both regimens. In the late relapse group, 4 of 5 patients in the VA group achieved cCR, and both patients in the D-CAG group achieved cCR. The median follow-up time was 19 months (IQR: 11-48.5 months). The median OS was 16 months in the whole cohort, with 19 months for the VA group and 11 months for the D-CAG group (P=0.189). Among the 30 patients who achieved cCR after salvage chemotherapy (VA=15 and D-CAG=15), the DOR in the VA group demonstrated a significant advantage over that in the D-CAG group (not reaching vs 6 months, P=0.023). The median OS for the early relapse, late relapse, and refractory groups was 5, 21, and 18 months, respectively, with significantly better efficacy observed in the late relapse group (P=0.020). Four patients who received salvage treatment followed by allogeneic stem cell transplantation had no evidence of disease, demonstrating a survival advantage compared with nontransplant patients (P=0.007). The incidence of rash (27.3% vs 3.6%, P=0.047) and diarrhea (40.9% vs 7.1%, P=0.012) in the VA group was significantly higher than that in the D-CAG group. Conclusion: The VA and D-CAG regimens have comparable efficacy for elderly patients with RR-AML. Patients with late relapse demonstrated better efficacy with both regimens compared with the early relapse and refractory groups. 目的: 比较维奈克拉(VEN)联合阿扎胞苷(AZA)(VA)与地西他滨联合CAG(D-CAG)方案治疗老年复发难治性急性髓系白血病(RR-AML)的疗效及安全性。 方法: 前瞻性随机研究,采用随机信封,计划入组50例。纳入2021年1月至2024年6月上海市静安区北站医院采用VA或D-CAG两种方案挽救治疗的老年RR-AML患者,主要终点为客观缓解率(ORR)、复合完全缓解(cCR)率,次要终点为总生存(OS)、持续缓解时间(DOR)和安全性分析。 结果: 50例老年RR-AML患者接受至少1个疗程VA或D-CAG方案治疗并完成疗效和安全性评估,VA组22例,中位年龄63.0(60.8~69.3)岁,D-CAG组28例,中位年龄66.5(62.3~69.0)岁。患者DNA甲基化基因突变频率最高,VA组阳性8例(36.4%),D-CAG组阳性9例(32.1%)。VA组和D-CAG组的1个疗程ORR分别为68.2%(15/22)和53.6%(15/28),cCR率分别为68.2%(15/22)和46.4%(13/28),两组患者1个疗程ORR和cCR率差异均无统计学意义(均P>0.05)。伴骨髓增生异常相关基因突变(AML-MR)患者中VA组cCR率为85.7%(6/7),高于D-CAG组的40.0%(4/10)。根据患者疾病状态分为早期复发、晚期复发及难治三组。结果显示,早期复发患者采用两种再诱导方案的cCR率均不到40%;而晚期复发患者VA组5例中4例获得cCR,D-CAG组2例均获cCR。中位随访时间为19(11~48.5)个月,整体患者中位OS时间为16个月。VA组和D-CAG组的中位OS时间分别为19个月和11个月,两组间OS差异无统计学意义(P=0.189)。30例患者挽救化疗后达到cCR,VA和D-CAG组各15例,VA组患者DOR较D-CAG组存在显著优势(未达到对6个月,P=0.023)。早期复发、晚期复发及难治三组的中位OS时间分别为5、21及18个月,晚期复发组患者疗效明显更具优势(P=0.020)。4例挽救治疗后接受异基因造血干细胞移植患者均无病生存,与非移植患者相比预后存在优势(P=0.007)。VA组皮疹(27.3%对3.6%,P=0.047)及腹泻(40.9%对7.1%,P=0.012)发生率均高于D-CAG组。 结论: VA及D-CAG方案用于老年RR-AML的疗效相当,晚期复发的AML患者对于两种挽救化疗疗效优于早期复发及难治组。.
引用
- Liu ZY, Chu XG, Dong GP, et al. [Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991313. doi:10.3760/cma.j.cn121090-20250512-00224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。